Although screening and early detection of prostate cancer (PC) has been associated with a drop in prostate cancer specific mortality in the US population and in the European Randomized Study of Prostate Cancer (ERSPC), PSA testing leads to significant over-detection and over-treatment of localized disease [1, 2]. This evidence concerns the gene KLK3 and prostate carcinoma.